Surgery for paediatric cataract entails increased glaucoma risk
May 2nd 2008Paediatric cataract surgery, particularly when performed in patients under the age of nine months, entails a substantial risk of post-surgical glaucoma, according to a study published in the January 2008 issue of Investigative Ophthalmology and Visual Science.
Infection incidence increasing despite improving diagnoses
May 1st 2008The American Society of Cataract and Refractive Surgery (ASCRS) survey results for 2008 pointed out some changing trends in infectious keratitis after LASIK and PRK compared with previous surveys conducted in 2002 and 2005, said Terry Kim, MD.
Visian ICL "impressive" for myopic correction
May 1st 2008Outcomes in a cohort including more than 5000 eyes support the conclusion that an implantable collamer lens (Visian ICL; STAAR Surgical) is a safe, predictable, and very effective method for correcting high-to-moderate myopia, said John R. Moran, MD, PhD.
UV toxicity culprit in post-LASIK dry eye
May 1st 2008Hypoesthesia is not the origin of post-LASIK punctuate epithelial keratopathy or the so-called dry eye syndrome. Rather, these sequelae may represent a phototoxic effect of treatment with the ultraviolet excimer laser, said Carmen Barraquer-Coll, MD.
Should tear dysfunction be treated with nutritional supplements?
May 1st 2008Nutritional supplements seem to make sense as a treatment of tear dysfunction, according to Marian Macsai, MD. Dr Macsai tempered her assertion with the observation that no objective trials have been performed to support the use of nutritional supplements in patients with tear deficiency.
Spectral-domain optical coherence tomography represents step forward
April 30th 2008Spectral domain, three-dimensional (3-D), high-resolution optical coherence tomography (OCT) represents a step forward in OCT technology, with precise registration, complete data set acquisition, and improved coverage of the retina being the major advantages.
Breakthrough in understanding vascular biology may lead to safer and more effective anti-angiogenics
April 30th 2008VEGFb, a novel form of vascular endothelial growth factor (VEGF), an anti-angiogenic which is cytoprotective for retinal cells, can inhibit choroidal neovascularization significantly, according to preclinical results presented at this year's BIO National Venture Conference, held April 22?23 in Cambridge, US.
FDA approves expansion of NeoVista's Phase III CABERNET trial
April 23rd 2008The FDA has approved an expansion of the Phase III CABERNET (CNV Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) trial, which is evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy in wet age-related macular degeneration (AMD).
Arsenal of strategies enables safe surgery in IFIS eyes
April 21st 2008Cases of intraoperative floppy iris syndrome (IFIS) encompass a wide spectrum of severity, so it is important for surgeons to master several different strategies to increase the likelihood of achieving a safe outcome in these eyes.